
Voluson™ Virtual Academy
Vasa Previa Webinar
Why prenatal ultrasound diagnosis matters
Vasa previa occurs in an estimated 1 in 1,200 to 1 in 1,500 births¹ and, when undiagnosed, is associated with extremely high perinatal mortality¹ and other adverse outcomes. Ultrasound is a cornerstone of vasa previa diagnosis and plays an important role in determining an appropriate monitoring and treatment strategy, putting routine screening at the center of preventing avoidable perinatal deaths.
In this webinar, we'll look at how advanced ultrasound technologies, including color Doppler and volume imaging, can be an important adjunct to traditional 2D studies in making an accurate diagnosis.
What you'll learn
In this compelling webinar, Dr. Yinka Oyelese will:
Details
Wednesday, November 4, 2026
7:00 pm CST/8:00 pm EST
Register now to save your spot.
Register for webinar access
We expect this webinar to fill up rapidly, so please reserve your spot today. Don’t miss out on this in-depth learning opportunity.
Meet your speaker

Yinka Oyelese, MD, MRCOG, FACOG
Director of Obstetric Imaging, Beth Israel Deaconess Medical Center
Associate Professor, Harvard Medical School
¹ Yinka Oyelese et al., "Vasa Previa: The Impact of Prenatal Diagnosis on Outcomes," Obstetrics & Gynecology 103, no. 5, pt. 1 (2004): 937–42, https://doi.org/10.1097/01.AOG.0000123245.48645.98.
The opinions, beliefs and viewpoints expressed in this webinar are solely those of the presenters and do not necessarily reflect the opinions, beliefs and viewpoints of GE HealthCare. The authors are paid consultants for GE HealthCare and were compensated for the creation of this webinar.
JB14748US

GE HealthCare | Contact Us | Privacy Policy | | Terms and Conditions | Compliance | California Privacy Policy | Security | California Transparency in Supply Chain Act | Adverse Event Reporting
500 W. Monroe Street | Chicago, IL 60661
© 2026 GE HealthCare. GE is a trademark of General Electric Company. Used under trademark license.